Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (EPOC)

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: February 8, 2012
Last updated: August 7, 2014
Last verified: August 2014
A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (fingolimod) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy.

Condition Intervention Phase
Relapsing Remitting Multiple Sclerosis
Drug: Fingolimod
Drug: Interferon beta - 1a (IFN)
Drug: Glatiramer acetate (GA)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (Fingolimod) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for Multiple Sclerosis (MS) Therapy Change From Previous Disease Modifying Therapy (DMT)

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Change in Patient-reported Treatment Satisfaction [ Time Frame: Baseline, 6 months ]
    The Treatment Satisfaction Questionnaire for Medication (TSQM) contains 14 items assessing the following 4 domains: effectiveness (items 1 - 3), side effects (items 4 - 8), convenience (items 9 - 11) and global satisfaction (items 12 - 14). The primary outcome was measured on the global satisfaction domain. Item 12 scored as 1 (not at all confident) to 5 (extremely confident); item 13 scored as 1 (not at all certain) to 5 (extremely certain); and item 14 scored as 1 (extremely dissatisfied) to 7 (extremely satisfied). Responses to items were summed and transformed: specifically, TSQM v 1.4 domain scale scores were computed by adding the items loading on each domain. The lowest possible score was subtracted from the composite score and divided by the greatest possible score range. This provided a transformed score between 0 and 1 that was then multiplied by 100. The final transformed score ranges from 0 to 100, with higher scores indicating better treatment satisfaction.

Secondary Outcome Measures:
  • Number of Patients Who Experienced Adverse Events, Serious Adverse Events and Death [ Time Frame: 6 months ]
    Participants were monitored for adverse events, serious adverse events and death throughout the study.

  • Changes in Patient-reported Effectiveness, Side Effects and Convenience [ Time Frame: Baseline, 6 months ]
    TSQM v 1.4 domains for effectiveness, side effects and convenience were used to evaluate this outcome. The effectiveness domain for items 1 - 3 was scored as: 1 (extremely dissatisfied) to 7 (extremely satisfied). For the side effects domain, item 4 scored as 0(no) or 1(yes); item 5 scored as 1 (extremely bothersome) to 5 (not at all bothersome); and items 6 - 8 scored as 1 (a great deal) to 5 (not at all). For the convenience domain, items 9 and 10 scored as 1(extremely difficult) to 7 (extremely easy), and item 11 scored as 1 (extremely inconvenient) to 7 (extremely convenient). For each domain, scale scores were computed by adding the items loading on each domain. The lowest possible score was subtracted from the composite score and divided by the greatest possible score range. This provided a transformed score between 0 and 1 that was then multiplied by 100. The final transformed score ranges from 0 to 100, with higher scores indicating better treatment satisfaction.

  • Change in Patient-reported Depression [ Time Frame: Baseline, 6 months ]
    The Beck Depression Inventory (BDI-I) scale was used to measure this outcome. The scale consists of 21 items to assess the intensity of depression in clinical and normal patients. Each item is a list of four statements arranged in increasing severity about a particular symptom of depression. Each item was scored from 0 - 3. If more than one score was provided for an item, the maximum score was considered the item score. The total score was calculated as the sum of all individual items and then compared to a key to determine the depression's severity. The standard key ranges were: 0 - 9 indicated minimal depression; 10 - 18 indicated mild depression; 19 - 29 indicated moderate depression and 30 - 63 indicated severe depression. Higher total scores indicate more severe depressive symptoms.

  • Change in Patient-reported Health-related Quality-of-life Using the Short Form Health Survey v2 Acute (SF-36 v2 Acute) [ Time Frame: Baseline, 6 months ]
    The SF-36 is a health-related quality of life instrument used in numerous disease states, including MS (Brazier et al 1992). It is a self-administered survey that measures 8 domains of health including: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems and general mental health. Two summary scale scores can be calculated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Each domain was scored by adding the individual items from the domain and transforming the resulting scores into a 0 to 100 scale with higher scores indicating better health status or functioning.

Enrollment: 298
Study Start Date: January 2012
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fingolimod
Participants received 0.5 mg orally once a day.
Drug: Fingolimod
0.5 mg orally once a day
Other Name: Gilenya
Active Comparator: Standard Disease Modifying Therapy (DMT)
Participants received interferon beta-1a (IFN), 44 mcg subcutaneously 3 times a week or glatiramer acetate (GA), 20 mg subcutaneously once a day.
Drug: Interferon beta - 1a (IFN)
44 mcg subcutaneously three times a week
Other Name: Rebif
Drug: Glatiramer acetate (GA)
20 mg subcutaneously once a day
Other Name: Copaxone


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent must be obtained before any assessment is performed.
  • Patients must be diagnosed with relapsing remitting MS (RRMS) as defined by 2005 revised McDonald criteria (McDonald et al 2001, Polman et al 2005) (Appendix 2).
  • Patients who explicitly agree to be assigned to a treatment group that may receive or DMT after having been informed about their respective benefits and possible adverse events by the investigator.
  • Male or female patients aged 18-70 years.
  • An Expanded Disability Status Scale (EDSS) score of 0-6 inclusive.
  • Must have received continuous treatment with a single approved and indicated MS DMT for a minimum of 6 months prior to the screening visit. Patients must continue with this MS DMT until the randomization visit.
  • Naïve to treatment with fingolimod.

Exclusion Criteria:

  • A manifestation of MS other than those defined in the inclusion criteria.
  • A history of chronic disease of the immune system other than MS or a known immunodeficiency syndrome.
  • History of malignancy of any organ system.
  • Diagnosis of macular edema during Screening Phase.
  • Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS or to have positive HIV antibody test.
  • Patients who have received any live or live attenuated vaccines (including for varicella-zoster virus or measles) within 2 months prior to baseline.
  • Patients who have received total lymphoid irradiation or bone marrow transplantation.
  • History of selected immune system treatments and/or medications.
  • Any medically unstable condition, as assessed by the investigator.
  • Selected cardiovascular, or hepatic conditions
  • Selected abnormal laboratory values.
  • Patients with any other disease or clinical condition (including neurologic or psychiatric disorders) which may affect patient enrollment into the study and study medication use by the Investigators' opinion.
  • Participation in any clinical research study evaluating another not approved in Russia investigational drug or therapy within 6 months prior to baseline.
  • History of hypersensitivity to the study drug or to drugs of similar chemical classes.
  • Pregnant or nursing (lactating) women.

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01534182

Russian Federation
Novartis Investigative Site
Arkhangelsk, Russia, Russian Federation, 163045
Novartis Investigative Site
Barnaul, Russian Federation, 656024
Novartis Investigative Site
Belgorod, Russian Federation, 308007
Novartis Investigative Site
Kazan, Russian Federation, 420021
Novartis Investigative Site
Kemerovo, Russian Federation, 650066
Novartis Investigative Site
Khanty-Mansiysk, Russian Federation, 628012
Novartis Investigative Site
Kirov, Russian Federation, 610014
Novartis Investigative Site
Krasnodar, Russian Federation, 350086
Novartis Investigative Site
Kursk, Russian Federation, 305007
Novartis Investigative Site
Moscow, Russian Federation, 119992
Novartis Investigative Site
Moscow, Russian Federation, 127018
Novartis Investigative Site
N.Novgorod, Russian Federation, 603126
Novartis Investigative Site
Nizhniy Novgorod, Russian Federation, 603076
Novartis Investigative Site
Nizhny Novgorod, Russian Federation, 603155
Novartis Investigative Site
Novosibirsk, Russian Federation, 630087
Novartis Investigative Site
Perm, Russian Federation, 614990
Novartis Investigative Site
Saransk, Russian Federation, 430032
Novartis Investigative Site
Saratov, Russian Federation, 410030
Novartis Investigative Site
Smolensk, Russian Federation, 214019
Novartis Investigative Site
St. Petersburg, Russian Federation, 197376
Novartis Investigative Site
Tomsk, Russian Federation, 634050
Novartis Investigative Site
Tumen, Russian Federation, 625048
Novartis Investigative Site
Tver, Russian Federation, 170036
Novartis Investigative Site
Ufa, Russian Federation, 450000
Novartis Investigative Site
Ulyanovsk, Russian Federation, 432063
Novartis Investigative Site
Yaroslavl, Russian Federation, 150030
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT01534182     History of Changes
Other Study ID Numbers: CFTY720DRU01
Study First Received: February 8, 2012
Results First Received: June 11, 2014
Last Updated: August 7, 2014

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Relapsing Remitting Multiple Sclerosis (RRMS)
Disease Modifying Therapy (DMT)

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Glatiramer Acetate
Fingolimod Hydrochloride
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents
Antirheumatic Agents processed this record on May 25, 2017